The clinical research industry finally has a baseline for AI adoption, and the numbers confirm what many suspected: full implementation is still rare. As of late 2024, only 11% of surveyed sponsors and CROs had fully implemented AI in clinical trial activities, according to the WCG CenterWatch 2025 AI Benchmarking Report released November 17. The report draws on survey responses from more than 400 sponsors, CROs, and sites collected in September and October 2025, giving the industry its first structured baseline for comparing AI adoption across organization types.
The report's practical value lies in the benchmarking function itself. Clinical research organizations have had no common reference point for evaluating their own AI maturity. A site director at a mid-size academic center, for example, has had no credible way to know whether her team's use of AI in patient recruitment screening is ahead of the curve or a year behind competitors.
The report identifies where the industry sits today, which functional areas show the most realistic near-term efficiency gains, and what metrics organizations should use to calibrate strategy. Protocol design, trial start-up, and data management are among the areas drawing the strongest enthusiasm from respondents - areas where operational friction is highest and where time savings compound across a study's lifecycle.
Adoption is still mostly partial
Beyond the 11% with full implementation, another 22% of sponsors and CROs reported partial AI integration as of late 2024. That means the majority of organizations were still experimenting rather than executing at scale.
The gap between organizations with coordinated AI strategies and those without is widening faster than aggregate adoption numbers suggest. Major CROs are committing significant capital to AI infrastructure - ICON announced a $300 million multi-year digital investment. The report gives lagging organizations a documented target to close against rather than an abstract aspiration.
The metric to watch
The number worth tracking as this report circulates is how quickly partial-implementation rates convert into full deployment over the next survey cycle. If the 22% partial cohort does not meaningfully shrink by late 2026, it signals that operational barriers, not strategic intent, are the real constraint.
That distinction matters for where the industry directs its next round of investment. If operational friction is the bottleneck, new capital should flow toward workflow redesign and staff training rather than additional software acquisitions.
Why this matters for research and IT professionals
For professionals working across healthcare research, science, and IT, this baseline shifts the conversation from whether AI belongs in clinical trials to exactly where it creates measurable value. The report offers a concrete reference point for evaluating your own organization's AI maturity: if your team has scaled AI beyond pilot projects in protocol design or data management, you are ahead of the typical organization. If you are still in the experimentation phase, you have a quantifiable target - and evidence that converting partial implementation into full deployment is the industry's critical bottleneck over the next two years. That should shape both your professional development priorities and how you advocate for resources within your organization.
Your membership also unlocks:
